Meglimin is an oral antidiabetic medication used to treat Type 2 diabetes. It is important to ensure the purity of Meglimin to maintain its effectiveness and safety for patients. Meglimin impurities refer to any unintended substances or by-products that may be present in the medication. These impurities can impact the efficacy and safety of the medication and should be carefully monitored and controlled during the manufacturing process. Regulatory agencies have set limits on acceptable levels of Meglimin impurities to ensure patient safety.